Linical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥8 | -50.0% |
| 2025 | ¥16 | +6.7% |
| 2024 | ¥15 | +7.1% |
| 2023 | ¥14 | 0.0% |
| 2022 | ¥14 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥12,517M | ¥12,308M | ¥10,437M | ¥8,666M |
| Gross Profit | ¥4,162M | ¥3,778M | ¥2,376M | ¥1,124M |
| Operating Income | ¥1,257M | ¥726M | -¥584M | -¥2,073M |
| Pretax Income | ¥1,391M | ¥678M | -¥496M | -¥2,994M |
| Net Income | ¥1,004M | ¥338M | -¥539M | -¥3,330M |
| EPS | ¥44.47 | ¥14.98 | -¥23.87 | -¥147.41 |
| Operating Margin | 10.04% | 5.90% | -5.59% | -23.92% |
| Balance Sheet | ||||
| Total Assets | ¥17,465M | ¥18,540M | ¥16,775M | ¥12,000M |
| Total Equity | ¥7,581M | ¥8,235M | ¥7,253M | ¥3,976M |
| Total Liabilities | ¥9,883M | ¥10,305M | ¥9,522M | ¥8,023M |
| Cash | ¥7,042M | ¥7,465M | ¥7,040M | ¥5,204M |
| Interest-bearing Debt | ¥3,542M | ¥2,898M | ¥2,328M | ¥2,250M |
| Equity Ratio | 43.41% | 44.42% | 43.24% | 33.14% |
| D/E Ratio | 0.47 | 0.35 | 0.32 | 0.57 |
| Cash Flow | ||||
| Operating CF | ¥1,840M | ¥1,065M | ¥595M | -¥1,611M |
| Investing CF | -¥14M | -¥29M | -¥45M | ¥88M |
| Financing CF | -¥957M | -¥961M | -¥939M | -¥513M |
| Free CF | ¥1,826M | ¥1,033M | ¥587M | -¥1,644M |
| Efficiency | ||||
| ROE | 13.25% | 4.11% | -7.43% | -83.74% |
| ROA | 5.75% | 1.82% | -3.21% | -27.75% |
Latest IR Information
-
Notice Regarding Dividend Receipt from Consolidated Subsidiary
Received dividend from consolidated subsidiary LINICAL KOREA CO., LTD. Amount is 1,000 million Korean won (110 million yen), receipt date on August 5, 2026. It will be recorded as ordinary income in the individual financial statements for the fiscal year...
Read more -
Financial Results Briefing Materials for the Fiscal Year Ending March 2026
For the fiscal year ending March 2026, net sales were JPY 8,665 million, operating loss of JPY 2,073 million, and net loss attributable to the parent of JPY 3,329 million. Revenue declined and losses occurred due to delays in large-scale...
Read more
Latest News (5 items)
Company Information
About
Linical Co., Ltd., a global contract research organization, provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug discovery consulting services, such as market analysis and research of products in development, regulatory affairs, and licensing support. It also provides clinical trial evaluation, statistical analysis, medical writing, pharmacovigilance, clinical monitoring, and contract medical affairs services. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
